Sermorelin is a synthetic peptide that stimulates the pituitary gland to release growth hormone. It reproduces the first 29 amino acids of growth hormone-releasing hormone (GHRH), so it works differently from injecting recombinant human growth hormone (HGH) directly.
The U.S. Food and Drug Administration (FDA) approved sermorelin acetate as the brand-name product Geref, first as a diagnostic test (1990) and then for children with idiopathic growth hormone deficiency (1997). The manufacturer discontinued Geref in 2008, and the approvals were withdrawn effective June 18, 2009. No FDA-approved sermorelin product is marketed in the United States today; sermorelin offered by clinics is compounded.
The best-supported findings concern growth hormone stimulation and growth in children with growth hormone deficiency. Controlled-trial evidence for weight loss, muscle gain, sleep, longevity or general wellness in healthy adults is limited.
Medical information: Sermorelin acts on the growth hormone–insulin-like growth factor 1 (GH–IGF-1) axis. This page summarizes published research and regulatory records. It is not individualized medical advice, and suspected growth hormone deficiency (GHD) is diagnosed by a qualified endocrinology professional.
Information current as of September 29, 2026.
In this article
- Sermorelin at a glance
- What is sermorelin?
- How does sermorelin work?
- Is sermorelin FDA-approved?
- What was sermorelin originally used for?
- Sermorelin benefits: what does the evidence support?
- Does sermorelin help with weight loss?
- Sermorelin for muscle growth and recovery
- Sermorelin for anti-aging: what the evidence shows
- Does sermorelin improve sleep?
- Sermorelin side effects and safety
- What is the sermorelin dosage?
- Sermorelin vs HGH
- Is sermorelin banned in sports?
- Who should have a medical evaluation first?
- Frequently asked questions about sermorelin
- Summary
Sermorelin at a glance
| Item | Summary |
|---|---|
| Type | Synthetic GHRH(1-29) analog; a growth hormone secretagogue |
| Mechanism | Binds GHRH receptors on pituitary somatotroph cells, prompting release of the body’s own growth hormone |
| Former brand | Geref (EMD Serono) |
| FDA approvals | December 28, 1990 (diagnostic use); September 26, 1997 (children with idiopathic GHD and growth failure) |
| Withdrawal | Discontinued by the manufacturer in 2008; approvals withdrawn effective June 18, 2009. In 2013 FDA determined the withdrawal was not for reasons of safety or effectiveness. |
| Current U.S. status | No FDA-approved sermorelin product marketed; compounded versions are not FDA-approved |
| Best-supported use | Diagnostic testing and pediatric GHD (historical) |
| Sports | Prohibited by the World Anti-Doping Agency (WADA) and the U.S. Anti-Doping Agency (USADA) |
What is sermorelin?
Sermorelin is a synthetic version of the first 29 amino acids of human GHRH, the portion responsible for much of the hormone’s growth hormone-releasing activity. Natural GHRH is produced in the hypothalamus and travels to the pituitary gland, where it signals specialized cells called somatotrophs to make and release growth hormone.
Sermorelin is not growth hormone itself. It is a growth hormone secretagogue that acts through the GHRH receptor, which is why sermorelin and recombinant HGH are not interchangeable products.
How does sermorelin work?
The basic pathway is: sermorelin → GHRH receptor in the pituitary → growth hormone release → increased downstream IGF-1 signaling.
After sermorelin activates GHRH receptors, the pituitary releases the body’s own growth hormone. Growth hormone acts on the liver and other tissues, in part by prompting production of IGF-1. Together, growth hormone and IGF-1 contribute to growth, metabolism, bone biology, protein turnover and body composition.
A pharmacology review in BioDrugs reports that intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary (Prakash & Goa, 1999). Because the effect depends on the pituitary responding, sermorelin needs functioning pituitary tissue. Recombinant growth hormone supplies the hormone directly and does not.
Is sermorelin FDA-approved?
Historical approvals
Geref, containing sermorelin acetate, was manufactured by EMD Serono. FDA approved NDA 19-863 on December 28, 1990, for evaluating the ability of the pituitary somatotroph to secrete growth hormone. It approved NDA 20-443 on September 26, 1997, for treating idiopathic growth hormone deficiency in children with growth failure (Federal Register, 2013).
Withdrawal of approval
EMD Serono notified FDA in 2008 that it was discontinuing Geref (July 11 for the 0.05 mg formulation and December 2 for the 0.5 mg and 1.0 mg formulations) and asked for the applications to be withdrawn. FDA withdrew the approvals effective June 18, 2009. On March 4, 2013, FDA published its determination that the Geref products “were not withdrawn for reasons of safety or effectiveness” (Federal Register, 2013).
That determination concerns the historical Geref products. It does not make current sermorelin products FDA-approved.
Compounded sermorelin
Sermorelin is currently offered by some compounding pharmacies and wellness clinics. FDA states that compounded drugs are not FDA-approved and that the agency does not review their safety, effectiveness or quality before they are marketed (FDA: Compounding and the FDA). Describing compounded sermorelin as “FDA-approved” is therefore inaccurate, even though Geref once held approval.
What was sermorelin originally used for?
Sermorelin had two historical medical roles.
- Diagnostic testing. A single intravenous dose was used to check whether the pituitary could secrete growth hormone when stimulated.
- Pediatric treatment. Daily subcutaneous injections were used in some children with idiopathic growth hormone deficiency.
In a multicenter, open-label study by the Geref International Study Group, 110 previously untreated prepubertal children with growth hormone deficiency received 30 micrograms per kilogram of GHRH(1-29) daily by subcutaneous injection at bedtime. Among the 86 children eligible for efficacy analysis, mean height velocity rose from 4.1 cm per year at baseline to 8.0 cm per year at six months and 7.2 cm per year at 12 months. The authors reported that the treatment was well tolerated (Thorner et al., 1996).
The BioDrugs review concluded that limited data suggested sermorelin was effective in some prepubertal children with idiopathic growth hormone deficiency. It also noted that the effect on final adult height had not been determined, that the recommended dose had not been directly compared with somatropin, and that height-velocity increases were smaller than those reported in children receiving once-daily somatropin (Prakash & Goa, 1999).
These findings come from children with a diagnosed deficiency. They are not evidence about healthy adults.
Sermorelin benefits: what does the evidence support?
Sermorelin marketing often groups many possible benefits together, including higher growth hormone, muscle development, lower body fat, better sleep, faster recovery, more energy, improved skin and better cognition. The strength of evidence differs for each claim.
| Claim | What the sources reviewed show |
|---|---|
| Raises growth hormone | Supported: sermorelin stimulates pituitary growth hormone release in people whose pituitary can respond |
| Increases growth in children with GHD | Supported by historical pediatric studies (see above) |
| Weight loss | No obesity trials of sermorelin comparable to those behind approved weight-management drugs were identified |
| Muscle growth, strength, recovery | No large, high-quality trials in healthy adults were identified |
| Sleep | Findings on GHRH and sleep are mixed; no modern trials establishing sermorelin as a treatment for insomnia were identified |
| Anti-aging | No approved indication; USADA describes robust clinical evidence for anti-aging effects as lacking |
Results from other GHRH analogs cannot be attributed to sermorelin. For example, a randomized trial in adults with and without mild cognitive impairment used tesamorelin, not sermorelin. Over 20 weeks it reported a favorable effect on cognition, a 117% rise in IGF-1 and a 7.4% reduction in body fat; adverse events were reported by 68% of treated adults versus 36% on placebo (Baker et al., 2012).
Does sermorelin help with weight loss?
Sermorelin is sometimes marketed as a “fat-burning peptide.” Growth hormone influences fat metabolism and body composition, so raising growth hormone or IGF-1 could plausibly change fat and lean tissue. A biological mechanism, however, is not evidence of clinically meaningful weight loss.
The sources reviewed identify no large Phase 3 obesity trials of sermorelin. Medicines with that kind of evidence are a separate category; investigational examples covered on this site include enicepatide and petrelintide, both of which remain unapproved.
Sermorelin for muscle growth and recovery
Growth hormone and IGF-1 take part in tissue growth and protein metabolism, which is why athletes and bodybuilders have shown interest in compounds that stimulate the GH axis. The sources reviewed do not identify large, high-quality trials showing that sermorelin improves strength, athletic performance or recovery in healthy adults.
Competitive athletes face a regulatory barrier. WADA’s Prohibited List names sermorelin among the growth hormone-releasing hormone analogs in its peptide hormones category, and USADA states that sermorelin is prohibited (WADA Prohibited List; USADA). USADA notes that a therapeutic use exemption is “highly unlikely” to be approved because sermorelin is not a first-line treatment for growth hormone deficiency.
Sermorelin for anti-aging: what the evidence shows
Growth hormone secretion declines with age, but a normal age-related decline is not in itself a disease. The Endocrine Society’s 2023 scientific statement on hormones and aging reported that, in unselected older populations, the harms of growth hormone and sex steroids outweighed their benefits, and noted that some hormonal “remedies” promoted by the anti-aging industry may do more harm than good (Cappola et al., 2023).
USADA states that “robust clinical evidence for anti-aging effects is lacking and remains controversial” (USADA). No clinical trial identified in the sources reviewed shows that compounded sermorelin reverses aging, extends lifespan or prevents dementia.
Does sermorelin improve sleep?
Natural growth hormone secretion is linked to sleep, especially deeper stages, and sermorelin is often taken at night. That association has led to claims that sermorelin improves sleep quality. Experimental work on GHRH and sleep has produced mixed, context-dependent results, and the sources reviewed identify no modern trials establishing sermorelin as a treatment for insomnia or other sleep disorders.
Persistent sleep problems have established causes, such as sleep apnea, insomnia disorder, medication effects, depression, restless legs syndrome and circadian rhythm disorders. A clinician evaluates these before attributing symptoms to low growth hormone.
Sermorelin side effects and safety
In pediatric studies, sermorelin was generally well tolerated. The BioDrugs review identified transient facial flushing and injection-site pain as the most commonly reported adverse events (Prakash & Goa, 1999). The Geref prescribing information reported local injection reactions (pain, redness or swelling) in roughly one in six patients.
USADA lists swelling and edema, joint and nerve pain, insulin resistance and diabetes risk, and hypertension among the concerns associated with raising growth hormone in athletes, and it describes contamination as a risk of products from unregulated sources (USADA). Long-term safety evidence for compounded sermorelin in otherwise healthy adults is limited.
Compounded products add a separate risk. FDA notes that compounded drugs do not undergo premarket quality review, so contamination or incorrect strength can occur (FDA). That risk applies with particular force to injectable peptides.
What is the sermorelin dosage?
No FDA-approved adult sermorelin dosage exists for anti-aging, bodybuilding, weight loss, sleep or general wellness. Doses advertised by clinics are not an FDA-established regimen.
The historical pediatric regimen studied by the Geref International Study Group was about 30 micrograms per kilogram per day by subcutaneous injection in children with growth hormone deficiency (Thorner et al., 1996). That figure describes a supervised pediatric research and treatment setting. It is not an adult dose recommendation. Compounded preparations can also differ in concentration, formulation and stability, and dosing of any drug that changes GH and IGF-1 signaling belongs in a physician’s hands.
Sermorelin vs HGH
Sermorelin and human growth hormone act on the same endocrine system at different points.
| Feature | Sermorelin | Recombinant HGH |
|---|---|---|
| What it is | GHRH analog | Growth hormone |
| Main action | Stimulates pituitary growth hormone release | Directly supplies growth hormone |
| Needs a functioning pituitary response | Yes | No |
| FDA-approved product currently marketed | No | Several |
| Role in adult GHD guidelines | Not a standard replacement therapy | Established replacement therapy |
| Common source today | Compounding pharmacies | FDA-approved prescription products |
The Endocrine Society’s clinical practice guideline on adult growth hormone deficiency recommends growth hormone replacement in appropriately selected adults with confirmed deficiency. It advises that diagnosis generally requires biochemical testing, including growth hormone stimulation testing in most cases, rather than treating nonspecific symptoms (Molitch et al., 2011).
Is sermorelin banned in sports?
Yes, for athletes subject to WADA rules. WADA’s Prohibited List names sermorelin among the growth hormone-releasing hormone analogs prohibited both in and out of competition, and USADA identifies it as prohibited (WADA; USADA). A clinic prescription does not make a prohibited substance acceptable under anti-doping rules, and tested athletes verify medications and exemption requirements through their anti-doping organization.
Who should have a medical evaluation first?
Fatigue, lower muscle mass, poor sleep, increased body fat and reduced exercise capacity are the symptoms most often used to market sermorelin. They are nonspecific and have many causes.
Adult GHD is a medical diagnosis. It can persist from childhood or develop later from pituitary or hypothalamic disease. According to the Endocrine Society guideline, confirmation generally relies on stimulation testing except in certain clearly established genetic or structural situations. A random growth hormone level is usually not enough because secretion is pulsatile, and IGF-1 must be interpreted in clinical context (Molitch et al., 2011).
Frequently asked questions about sermorelin
What does sermorelin do?
Sermorelin activates GHRH receptors in the pituitary gland, which stimulates release of endogenous growth hormone and can raise downstream IGF-1 signaling.
Is sermorelin the same as HGH?
No. HGH therapy supplies growth hormone directly. Sermorelin stimulates the pituitary to release the body’s own growth hormone, so it requires a functioning pituitary response.
Is sermorelin FDA-approved in 2026?
No FDA-approved sermorelin product is currently marketed in the United States. Geref was approved in 1990 and 1997 and withdrawn effective June 18, 2009 after the manufacturer discontinued it. FDA determined in 2013 that the withdrawal was not for reasons of safety or effectiveness. Compounded sermorelin is not FDA-approved.
Why was sermorelin discontinued?
EMD Serono discontinued Geref in 2008 and requested withdrawal of the applications, and FDA later found that the products were not withdrawn for safety or effectiveness reasons. The determination does not address the safety or effectiveness of today’s compounded formulations.
Does sermorelin increase growth hormone?
Yes. Stimulating pituitary growth hormone release is sermorelin’s basic pharmacological action.
Does sermorelin raise IGF-1?
It can. Growth hormone prompts IGF-1 production, so repeated stimulation of the GH pathway may raise circulating IGF-1. The size of the response depends on pituitary function, dose, age and individual physiology.
Does sermorelin cause weight loss?
Sermorelin has not been established as an obesity medication in large modern trials. Effects of the GH–IGF-1 pathway on body composition are not equivalent to proven long-term weight loss.
Does sermorelin build muscle?
The sources reviewed identify no strong evidence that sermorelin reliably increases strength or athletic performance in healthy adults. It is prohibited for athletes under WADA rules.
Is sermorelin an anti-aging treatment?
No anti-aging indication is approved. USADA describes the clinical evidence for anti-aging effects as lacking, and the Endocrine Society reported that growth hormone’s harms outweighed benefits in unselected older populations.
What are the most common sermorelin side effects?
Historical clinical data most often describe injection-site pain, redness or swelling and transient facial flushing. Compounded products add quality risks because they do not undergo FDA premarket review.
Can you buy sermorelin online?
Sermorelin is advertised by some telehealth providers, compounding pharmacies, wellness clinics and unregulated websites. FDA cautions that compounded drugs are not FDA-approved and that poor manufacturing can cause contamination or incorrect strength. USADA cautions specifically about black-market sources.
Summary
Sermorelin is a GHRH analog with a documented medical history. It stimulates pituitary growth hormone release, and historical studies showed increased growth velocity in some children with growth hormone deficiency. Geref was FDA-approved for diagnostic (1990) and pediatric (1997) use, was discontinued in 2008, and had its approvals withdrawn effective June 18, 2009, for reasons FDA later stated were not related to safety or effectiveness.
Compounded sermorelin sold today is not FDA-approved. Evidence for weight loss, muscle gain, better sleep, longevity or general anti-aging remains limited, and results from other GHRH analogs such as tesamorelin do not transfer to sermorelin. For suspected growth hormone deficiency, the Endocrine Society guideline describes diagnostic evaluation, generally including stimulation testing, followed by medically supervised growth hormone replacement in confirmed cases.
Sources
- FDA / Federal Register (March 4, 2013): Determination that Geref (sermorelin acetate) was not withdrawn from sale for reasons of safety or effectiveness. Approval dates, indications, the 2008 discontinuation and the June 18, 2009 withdrawal.
- FDA: Compounding and the FDA, questions and answers. Regulatory status of compounded drugs.
- Thorner et al. (1996), J Clin Endocrinol Metab: Once daily subcutaneous GHRH therapy accelerates growth in GH-deficient children. Geref International Study Group (PubMed 8772599).
- Prakash & Goa (1999), BioDrugs: Sermorelin, a review of its use in the diagnosis and treatment of children with idiopathic GHD (PubMed 18031173).
- Baker et al. (2012), Arch Neurol: Effects of GHRH on cognitive function in adults with mild cognitive impairment and healthy older adults. Tesamorelin trial (PubMed 22869065).
- Molitch et al. (2011), J Clin Endocrinol Metab: Evaluation and treatment of adult growth hormone deficiency, an Endocrine Society clinical practice guideline.
- Cappola et al. (2023), J Clin Endocrinol Metab: Hormones and Aging, an Endocrine Society scientific statement.
- World Anti-Doping Agency: The Prohibited List.
- USADA: What should athletes know about sermorelin?